1:49 PM
 | 
Aug 24, 2017
 |  BC Extra  |  Clinical News

Apellis' C3 inhibitor slows progression of dry AMD

Editor's Note: This article was updated on Aug 24, 2017 at 3:16 PM PDT

Apellis Pharmaceuticals Inc. (Crestwood, Ky.) said its lead candidate APL-2 met the primary endpoint of reducing lesion growth compared to sham procedure in the Phase II FILLY trial to treat geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) for which there are no approved treatments. Apellis CEO Cedric Francois told BioCentury the company plans to start Phase III testing of the

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >